724.75MMarket Cap-15.49P/E (TTM)
8.950High8.450Low839.08KVolume8.535Open8.470Pre Close7.30MTurnover1.02%Turnover RatioLossP/E (Static)85.06MShares14.44152wk High6.53P/B702.68MFloat Cap3.25052wk Low--Dividend TTM82.47MShs Float31.500Historical High--Div YieldTTM5.90%Amplitude0.600Historical Low8.695Avg Price1Lot Size
Anavex Life Sciences Stock Forum
Breakthrough: Anavex Alzheimer's Treatment Halts Disease Progression by Over One-Third
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences (Nasdaq: AVXL) has been granted a new U.S. Patent (No. 12,180,174) for crystalline forms of ANAVEX®2-73 (blarcamesine) dihydrogen phosphate salt. The patent covers crystalline forms, freebase, transdermal patches, and enteric coated oral dosage forms for neuroprotection and treatment of neuro...
Just
Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio
New Phase Iib/III Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
$Anavex Life Sciences (AVXL.US)$
I would like to wish everyone a Happy New Year
No comment yet